Generate Biomedicines, Inc. (GENB) vs Kestra Medical Technologies, Ltd. (KMTS)
A side-by-side comparison of Generate Biomedicines, Inc. and Kestra Medical Technologies, Ltd. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GENB
Generate Biomedicines, Inc.
$13.64HealthcareDelayed quote: Oct 6, 2026, 10:35 AM EDT
KMTS
Kestra Medical Technologies, Ltd.
$27.87HealthcareDelayed quote: Oct 6, 2026, 10:27 AM EDT
Total return — GENB vs KMTS
growth of $100 · dividends reinvested · last 1yGENB +10.0% (+10.0%/yr)KMTS +21.7% (+21.7%/yr)KMTS compounded faster over this window
GENB KMTS
GENB vs KMTS: by the numbers
- •GENB is the larger company ($1.75B vs $1.63B market cap).
- •Both run net losses; KMTS's is the smaller (-140.43% vs -636.99% net margin).
Metrics side by side
Valuation
| Metric | GENB | KMTS |
|---|---|---|
| P/S ratio | N/A | 15.30 |
| P/B ratio | 3.83 | 7.35 |
Profitability
| Metric | GENB | KMTS |
|---|---|---|
| Gross margin | 100.00% | 53.89% |
| Operating margin | -737.04% | -134.48% |
| Net margin | -636.99% | -140.43% |
| ROE | N/A | -67.40% |
| ROIC | -94.79% | -47.99% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.